Roy S Herbst

Summary

Affiliation: Yale University
Country: USA

Publications

  1. doi request reprint Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Lancet 377:1846-54. 2011
  2. pmc Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer
    Keiko Shibuya
    Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 69:1534-43. 2007
  3. ncbi request reprint Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade
    Wenjuan Wu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 97, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 6:471-83. 2007
  4. doi request reprint Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy
    William N William
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Am J Clin Oncol 33:148-52. 2010
  5. ncbi request reprint Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer
    Amir Onn
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:8613-9. 2004
  6. pmc Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis
    Osamu Takahashi
    Department of Radiation Oncology The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Cancer Res 18:1641-54. 2012
  7. ncbi request reprint Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice
    Wenjuan Wu
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030, USA
    Mol Cancer Ther 6:2652-63. 2007
  8. pmc Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice
    Satoshi Itasaka
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 67:870-8. 2007
  9. pmc Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, Section of Thoracic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 28:4747-54. 2010
  10. ncbi request reprint Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer
    Roy S Herbst
    The M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:4743-50. 2007

Collaborators

Detail Information

Publications67

  1. doi request reprint Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Lancet 377:1846-54. 2011
    ....
  2. pmc Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer
    Keiko Shibuya
    Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 69:1534-43. 2007
    ....
  3. ncbi request reprint Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade
    Wenjuan Wu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 97, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 6:471-83. 2007
    ....
  4. doi request reprint Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy
    William N William
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Am J Clin Oncol 33:148-52. 2010
    ..The aim of this phase 2 study was to investigate the use of docetaxel and vinorelbine in the frontline and second-line setting in patients with incurable non-small-cell lung cancer...
  5. ncbi request reprint Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer
    Amir Onn
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:8613-9. 2004
    ..The purpose is to evaluate whether inhibition of epidermal growth factor receptor (EGFR) activation by PKI166, an EGFR-tyrosine kinase inhibitor, affects growth of human lung cancer implanted orthotopically into the lungs of nude mice...
  6. pmc Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis
    Osamu Takahashi
    Department of Radiation Oncology The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Cancer Res 18:1641-54. 2012
    ....
  7. ncbi request reprint Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice
    Wenjuan Wu
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030, USA
    Mol Cancer Ther 6:2652-63. 2007
    ..Our findings provide an additional explanation for the susceptibility of lung cancers to treatment with EGFR tyrosine kinase inhibitors...
  8. pmc Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice
    Satoshi Itasaka
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 67:870-8. 2007
    ....
  9. pmc Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, Section of Thoracic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 28:4747-54. 2010
    ..This randomized phase II trial was designed to select a cetuximab plus chemotherapy regimen for phase III evaluation...
  10. ncbi request reprint Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer
    Roy S Herbst
    The M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:4743-50. 2007
    ..A single-arm phase I and II study of bevacizumab plus erlotinib demonstrated encouraging efficacy, with a favorable safety profile...
  11. ncbi request reprint Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer
    Ralph G Zinner
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:2449-56. 2005
    ..The primary objectives of this study were to determine the efficacy and tolerability of a pemetrexed-carboplatin combination as first-line therapy in patients with advanced nonsmall cell lung cancer...
  12. ncbi request reprint Toxicities of antiangiogenic therapy in non-small-cell lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 8:S23-30. 2006
    ..Additionally, further investigation is necessary to determine risk factors for hemorrhage with antiangiogenic agents...
  13. doi request reprint A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer
    Edward S Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 115:1713-22. 2009
    ..Cetuximab in combination with docetaxel was examined in chemotherapy-refractory/resistant patients with advanced nonsmall-cell lung cancer (NSCLC) to determine response rate, survival, safety, and pharmacokinetics (PK)...
  14. doi request reprint Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer
    Ralph G Zinner
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 73:119-27. 2009
    ....
  15. doi request reprint Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
    Hai T Tran
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030, USA
    Invest New Drugs 29:499-505. 2011
    ..To assess the pharmacokinetics and evaluate potential drug-drug interactions between erlotinib, paclitaxel and carboplatin...
  16. ncbi request reprint Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors
    Hai T Tran
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 54:308-14. 2004
    ..The present study was designed to determine the toxicity and pharmacokinetics of carboplatin in combination with TNP-470 in comparison with the doublet regimen of paclitaxel and carboplatin in patients with solid tumors...
  17. ncbi request reprint Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin
    Roy S Herbst
    Department of Thoracic and Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:3804-14. 2002
    ..We present the initial results of a dose-finding clinical trial of recombinant human endostatin (rh-Endo) that examined potential surrogates for response to antiangiogenic therapy...
  18. pmc Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial
    Charles Lu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030 4009, USA
    J Natl Cancer Inst 102:859-65. 2010
    ..CONCLUSIONS The addition of AE-941 to chemoradiotherapy did not improve overall survival in patients with unresectable stage III NSCLC. This study does not support the use of shark cartilage-derived products as therapy for lung cancer...
  19. ncbi request reprint Current management of advanced non-small cell lung cancer: targeted therapy
    Takeshi Isobe
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 32:315-28. 2005
    ..Achievement of these goals will hopefully lead to incorporation of biological therapy into the current anticancer arsenal, for the benefit of lung cancer patients...
  20. ncbi request reprint Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer
    Amir Onn
    Department of Thoracic, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 10:136-43. 2004
    ..Then we correlated these data with patient clinical outcome...
  21. ncbi request reprint TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
    Roy S Herbst
    University of Texas M D Anderson Cancer Center, Houston, USA
    J Clin Oncol 23:5892-9. 2005
    ..Erlotinib was combined with chemotherapy to determine if it could improve the outcome of patients with NSCLC...
  22. ncbi request reprint Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome
    Amir Onn
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 57, Houston, TX 77030, USA
    Radiology 237:342-7. 2005
    ..To retrospectively identify radiographic characteristics of stage I non-small cell lung cancer (NSCLC) that may correlate with epidermal growth factor receptor (EGFR) or HER2 expression or with prognosis...
  23. doi request reprint Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer
    Emer O Hanrahan
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 15:3600-9. 2009
    ..In study 7, vandetanib monotherapy was inferior to carboplatin-paclitaxel. We performed an exploratory retrospective analysis of the relationship between baseline circulating VEGF concentrations and PFS...
  24. ncbi request reprint Angiogenesis as a target for cancer therapy
    Kerim Kaban
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Hematol Oncol Clin North Am 16:1125-71. 2002
    ..Still, there is much to learn about the machinery that tumors use to recruit new blood vessels, and the results of the clinical trials will show the best way to apply that knowledge for cancer therapy...
  25. ncbi request reprint Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 432, PO Box 301402, Houston, TX 77230 1402, USA
    J Clin Oncol 23:5578-87. 2005
    ....
  26. ncbi request reprint Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Department of Thoracic Head and Neck Medical Oncology, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030 4009, USA
    Expert Opin Investig Drugs 16:239-49. 2007
    ..Clinical development is also ongoing in other tumor types and encouraging evidence of antitumor activity has been reported in patients with metastatic hereditary medullary thyroid cancer...
  27. pmc Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice
    Jörg J Jacoby
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
    J Thorac Oncol 5:940-9. 2010
    ..To determine the effectiveness of PX-478 against lung tumors, we investigated HIF-1alpha expression in several lung cancer cell lines, both in vitro and in vivo, and treated orthotopic mouse models of human lung cancer with PX-478...
  28. ncbi request reprint Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors
    Darren W Davis
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 10:33-42. 2004
    ..The results, including tumor blood flow measured by positron emission tomography, were analyzed using a quadratic polynomial model...
  29. ncbi request reprint Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing d
    Ralph G Zinner
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Lung Cancer 44:99-110. 2004
    ....
  30. ncbi request reprint Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung canc
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, Biostatistics and Diagnostic Radiology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 23:2544-55. 2005
    ..Preclinical data in various xenograft models produced greater growth inhibition than with either agent alone. Additionally, both agents have demonstrated benefit in patients with previously treated non-small-cell lung cancer (NSCLC)...
  31. ncbi request reprint Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    J Clin Oncol 22:785-94. 2004
    ..This phase III, randomized, placebo-controlled, double-blind trial evaluated gefitinib plus paclitaxel and carboplatin in chemotherapy-naive patients with advanced NSCLC...
  32. ncbi request reprint Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice
    Amir Onn
    Department of Thoracic Head and Neck Medical Oncology, Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:5532-9. 2003
    ..This study was conducted to develop biologically relevant animal models of human lung cancer that are reproducible, inexpensive, and easy to perform...
  33. doi request reprint Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer
    Yun Oh
    Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 26:1135-41. 2008
    ..This phase II trial of enzastaurin was conducted to determine the 6-month progression-free survival (PFS) rate in advanced, metastatic NSCLC...
  34. ncbi request reprint Targeted therapy in non-small-cell lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Oncology (Williston Park) 16:19-24. 2002
    ..It is even possible that these new biologic therapies will be used together as rational combinations (based on pathologic diagnosis) for advanced non-small-cell lung cancer...
  35. ncbi request reprint [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer
    Ryohei Sasaki
    Department of Radiation Oncology, Unit 97, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:1136-43. 2005
    ..To determine whether the standardized uptake value (SUV) of [(18)F]fluorodeoxyglucose uptake by positron emission tomography could be a prognostic factor for non-small-cell lung cancer (NSCLC)...
  36. ncbi request reprint A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology and Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 9:4108-15. 2003
    ....
  37. ncbi request reprint Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:4440-7. 2002
    ..TNP-470 was administered with paclitaxel to adults with solid tumors to define the safety and optimal dose of the combination regimen and to assess pharmacokinetic interactions...
  38. ncbi request reprint Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 13:6175-81. 2007
    ..Based on supporting preclinical studies, we undertook a Phase II trial of pertuzumab in patients with recurrent non-small cell lung cancer (NSCLC)...
  39. ncbi request reprint KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
    Erminia Massarelli
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 13:2890-6. 2007
    ..In contrast, KRAS mutation has been shown to predict poor response to such therapy. We tested the utility of combinations of these three markers in predicting response and survival in patients with NSCLC treated with EGFR-TKIs...
  40. doi request reprint Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study
    Chaan S Ng
    Department of Radiology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Comput Assist Tomogr 33:460-5. 2009
    ..To compare blood flow measurements of tumors assessed by perfusion computed tomography (pCT) and the clinical gold standard of 15O-labeled water positron emission tomography (15O-PET)...
  41. pmc Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030 4009, USA
    Lancet Oncol 11:619-26. 2010
    ..These results supported investigation of the combination in this larger, definitive phase 3 trial (ZODIAC)...
  42. ncbi request reprint Phase I study of recombinant human endostatin in patients with advanced solid tumors
    Roy S Herbst
    Department of Thoracic and Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:3792-803. 2002
    ..We evaluated recombinant human endostatin (rh-Endo) in a phase I trial designed to assess safety, pharmacokinetics, and serum markers of angiogenesis in patients with solid tumors...
  43. pmc CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma
    Pierre Saintigny
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Res 73:571-82. 2013
    ..Expression of CXCL5 was regulated by promoter methylation. The CXCR2 axis may be an important target in smoking-related lung adenocarcinoma...
  44. ncbi request reprint The BATTLE trial: personalizing therapy for lung cancer
    Edward S Kim
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Discov 1:44-53. 2011
    ..BATTLE establishes the feasibility of a new paradigm for a personalized approach to lung cancer clinical trials...
  45. ncbi request reprint Angiogenesis and lung cancer: prognostic and therapeutic implications
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030 4009, USA
    J Clin Oncol 23:3243-56. 2005
    ....
  46. ncbi request reprint Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program
    Sheeba K Thomas
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 7:326-31. 2006
    ..The primary objective of this retrospective study was to investigate the potential role of East Asian ethnicity or origin in predicting response to gefitinib in advanced-stage non-small-cell lung cancer (NSCLC)...
  47. pmc Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome
    Nathan T Ihle
    Department of Experimental Therapeutics, The Hamon Center for Therapeutic Oncology Research and Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA
    J Natl Cancer Inst 104:228-39. 2012
    ..However, in non-small cell lung cancer (NSCLC), the evidence that KRAS mutation is a predictive factor is conflicting...
  48. ncbi request reprint Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition
    Seung Hyun Oh
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 432, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 5:2685-95. 2006
    ..Our findings indicate that IGFBP-3 may be a promising anti-invasive and antimetastatic therapeutic agent in lung cancer...
  49. ncbi request reprint Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 30:30-8. 2003
    ....
  50. ncbi request reprint New targets for the treatment of advanced non-small cell lung cancer
    Erminia Massarelli
    Department of Thoracic Head and Neck Medical Oncology, University of Texas, M D Anderson Cancer Center, P O Box 432, Houston, TX 77030, USA
    Cancer Chemother Biol Response Modif 20:717-61. 2002
  51. pmc Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324
    George R Blumenschein
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Clin Oncol 29:2312-8. 2011
    ..We report a phase II trial testing the combination of cetuximab with chemoradiotherapy (CRT) in unresectable stage III NSCLC...
  52. ncbi request reprint Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial
    Ritsuko Komaki
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 58:1369-77. 2004
    ..To determine the ability of amifostine to reduce the severity and/or incidence of the acute toxicities of concurrent chemotherapy and radiotherapy (RT) for non-small-cell lung cancer...
  53. doi request reprint Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy
    Roy S Herbst
    Section of Thoracic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Clin Lung Cancer 10:20-7. 2009
    ....
  54. ncbi request reprint Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lung Cancer 6:S7-S19. 2004
    ..Therefore, although more work is required, data indicate that HER1/EGFR inhibitors will play an important role in treating patients with NSCLC...
  55. ncbi request reprint Phase I participants' views of quality of life and trial participation burdens
    Marlene Zichi Cohen
    Health Science Center at Houston, School of Nursing, The University of Texas, 6901 Bertner Ave, Rm 797, Houston, TX 77030, USA
    Support Care Cancer 15:885-90. 2007
    ..To address these responsibilities, analysis was conducted on participants' views of their experiences of a phase I trial, including the associated burdens and what constitutes QOL...
  56. doi request reprint Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC
    Roy S Herbst
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 13:1166-76. 2008
    ..In addition, the application of such personalized therapy will also depend on the availability of validated screening methods...
  57. pmc Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma
    Tina Cascone
    Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Invest 121:1313-28. 2011
    ..Understanding stromal signaling may be critical for developing biomarkers for angiogenesis inhibitors and improving combination regimens...
  58. ncbi request reprint Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668
    Darren W Davis
    Department of Cancer Biology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 11:678-89. 2005
    ....
  59. ncbi request reprint Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:3815-25. 2002
    ....
  60. ncbi request reprint Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:779-85. 2007
    ..To retrospectively compare outcomes for patients with unresectable locally advanced non-small-cell lung cancer (NSCLC) treated at our institution with concurrent chemoradiation with or without induction chemotherapy...
  61. ncbi request reprint Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine
    Xian Zhou
    Department of Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Trials 5:181-93. 2008
    ..Our goals are to characterize the molecular signature of individual tumors, offer the best-fit targeted therapies to patients in a study, and identify promising agents for future development...
  62. ncbi request reprint Pemetrexed in advanced NSCLC: a review of the clinical data
    Ralph G Zinner
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology (Williston Park) 18:54-62. 2004
    ..Pemetrexed is an important addition to the armamentarium of medicines used to treat thoracic malignancies, and merits study in combination with other drugs having novel mechanisms of action...
  63. ncbi request reprint Gefitinib: current and future status in cancer therapy
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Adv Hematol Oncol 1:466-72. 2003
    ..This article provides a detailed overview of gefitinib, the rationale for its use in a wide range of tumor types, and the current clinical development status of this novel agent...
  64. ncbi request reprint Erlotinib (Tarceva): an update on the clinical trial program
    Roy S Herbst
    The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    Semin Oncol 30:34-46. 2003
    ....
  65. ncbi request reprint Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data
    Ralph G Zinner
    Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Lung Cancer 5:S67-74. 2004
    ..Pemetrexed is clearly a useful agent in the treatment of thoracic malignancies, and is worthy of further study in combination with other drugs having novel mechanisms of action...
  66. ncbi request reprint Review of epidermal growth factor receptor biology
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 59:21-6. 2004
    ..When used in combination with cytotoxic treatments, chemotherapy, and radiation, EGFR inhibitors have been able to potentiate their anticancer activity...
  67. ncbi request reprint Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer
    Roy S Herbst
    University of Texas M D Anderson Cancer Center, Thoracic Head and Neck Medicine Clinic, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    J Clin Oncol 28:2839-46. 2010
    ..To the best of our knowledge, this is the first in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and antitumor activity of multiple intravenous doses of rhApo2L/TRAIL in patients with advanced cancer...